



UT20 Rec'd PCT/PTO 26 MAR 2003

PATENT

13054.02320

#10

Box/seq

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Arthur LANDER, et al.

Serial No: 09/807,575

Filed: July 12, 2001

For: GLYPICAN FOR THE DETECTION AND  
TREATMENT OF HUMAN CARCINOMA

Art Unit: (Not Assigned)

Examiner: (Not Assigned)

**RESPONSE TO NOTICE TO COMPLY WITH  
REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

Box Sequence  
US PTO  
PO Box 2327  
Arlington, VA 22202

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


Commissioner for Patents  
Washington D.C. 20231, on

March 21, 2003

Date of Deposit

Heather B. Del Bosco

Name



03/21/03

Signature

Date

Dear Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures," dated March 3, 2003 enclosed please find a CD-ROM copy and a hardcopy of the requested corrected Sequence Listing are enclosed for your review.

Please charge any insufficiency or credit any overpayment to Deposit Account No. 50 2567. A copy of this document is enclosed.

**IN THE SPECIFICATION:**

Kindly enter the attached "Sequence Listing" into the specification of the above referenced application and delete any "Sequence listing" that may already exist within the specification.

**REMARKS**

A corrected substitute CRF CD ROM and a paper version of the "Sequence Listing" are provided herewith. Applicants hereby state that the contents of the CRF CD ROM and the paper version CRF are

identical. Further, this submission is made to correct errors in the previous submissions of this Sequence Listing. No new matter has been added.


The present CRF diskette has been examined with Checker 3.1 which reported that there were no errors in the listing.

Respectfully submitted,

REED SMITH CROSBY HEAFEY

Date: March 21, 2003

By: \_\_\_\_\_

  
Stefan J. Kirchanski  
Registration No. 36,568  
Attorney for Applicant(s)

1901 Avenue of the Stars, Suite 700  
Los Angeles, CA 90067  
Phone: (310) 734-5200  
Fax: (310) 734-5299



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/807,575	Arthur Lander	82351-0003-343054.0201

INTERNATIONAL APPLICATION NO.

PCT/US99/24176

28983

REED SMITH CROSBY HEAFEY LLP  
1901 AVENUE OF THE STARS, SUITE 700  
LOS ANGELES, CA 90067

RECEIVED

MAR 20 2003

I.A. FILING DATE

10/15/1999

PRIORITY DATE

10/16/1998

CONFIRMATION NO. 9101

371 FORMALITIES LETTER



\*OC000000009585920\*

Date Mailed: 03/04/2003

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Diskette
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination
- Small Entity Statement

Applicant's response filed 07/12/2001 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 09/14/2001 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
    - For Rules Interpretation, call (703) 308-4216
    - To Purchase PatentIn Software, call (703) 306-2600
    - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

ANITA D JOHNSON

Telephone: (703) 305-3661

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/807,575	PCT/US99/24176	82351.0003